Use of signals of positive and negative selection to distinguish cancer genes and passenger genes

  1. László Bányai
  2. Maria Trexler
  3. Krisztina Kerekes
  4. Orsolya Csuka
  5. László Patthy  Is a corresponding author
  1. Research Centre for Natural Sciences, Hungary
  2. National Institute of Oncology, Hungary

Abstract

A major goal of cancer genomics is to identify all genes that play critical roles in carcinogenesis. Most approaches focused on genes positively selected for mutations that drive carcinogenesis and neglected the role of negative selection. Some studies have actually concluded that negative selection has no role in cancer evolution. We have re-examined the role of negative selection in tumor evolution through the analysis of the patterns of somatic mutations affecting the coding sequences of human genes. Our analyses have confirmed that tumor suppressor genes are positively selected for inactivating mutations, oncogenes, however, were found to display signals of both negative selection for inactivating mutations and positive selection for activating mutations. Significantly, we have identified numerous human genes that show signs of strong negative selection during tumor evolution, suggesting that their functional integrity is essential for the growth and survival of tumor cells.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

The following previously published data sets were used

Article and author information

Author details

  1. László Bányai

    Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
    Competing interests
    The authors declare that no competing interests exist.
  2. Maria Trexler

    Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
    Competing interests
    The authors declare that no competing interests exist.
  3. Krisztina Kerekes

    Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
    Competing interests
    The authors declare that no competing interests exist.
  4. Orsolya Csuka

    Department of Pathogenetics, National Institute of Oncology, Budapest, Hungary
    Competing interests
    The authors declare that no competing interests exist.
  5. László Patthy

    Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
    For correspondence
    patthy.laszlo@ttk.mta.hu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1329-0484

Funding

Hungarian National Research, Development and Innovation Office (GINOP-2.3.2-15-2016-00001)

  • László Bányai
  • Maria Trexler
  • Krisztina Kerekes
  • László Patthy

Hungarian National Research, Development and Innovation Office (NVKP_16-1-2016-0005)

  • Orsolya Csuka

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Bányai et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,817
    views
  • 417
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. László Bányai
  2. Maria Trexler
  3. Krisztina Kerekes
  4. Orsolya Csuka
  5. László Patthy
(2021)
Use of signals of positive and negative selection to distinguish cancer genes and passenger genes
eLife 10:e59629.
https://doi.org/10.7554/eLife.59629

Share this article

https://doi.org/10.7554/eLife.59629

Further reading

    1. Cancer Biology
    2. Evolutionary Biology
    Susanne Tilk, Judith Frydman ... Dmitri A Petrov
    Research Article

    In asexual populations that don’t undergo recombination, such as cancer, deleterious mutations are expected to accrue readily due to genome-wide linkage between mutations. Despite this mutational load of often thousands of deleterious mutations, many tumors thrive. How tumors survive the damaging consequences of this mutational load is not well understood. Here, we investigate the functional consequences of mutational load in 10,295 human tumors by quantifying their phenotypic response through changes in gene expression. Using a generalized linear mixed model (GLMM), we find that high mutational load tumors up-regulate proteostasis machinery related to the mitigation and prevention of protein misfolding. We replicate these expression responses in cancer cell lines and show that the viability in high mutational load cancer cells is strongly dependent on complexes that degrade and refold proteins. This indicates that the upregulation of proteostasis machinery is causally important for high mutational burden tumors and uncovers new therapeutic vulnerabilities.

    1. Cancer Biology
    2. Cell Biology
    Kourosh Hayatigolkhatmi, Chiara Soriani ... Simona Rodighiero
    Tools and Resources

    Understanding the cell cycle at the single-cell level is crucial for cellular biology and cancer research. While current methods using fluorescent markers have improved the study of adherent cells, non-adherent cells remain challenging. In this study, we addressed this gap by combining a specialized surface to enhance cell attachment, the FUCCI(CA)2 sensor, an automated image analysis pipeline, and a custom machine learning algorithm. This approach enabled precise measurement of cell cycle phase durations in non-adherent cells. This method was validated in acute myeloid leukemia cell lines NB4 and Kasumi-1, which have unique cell cycle characteristics, and we tested the impact of cell cycle-modulating drugs on NB4 cells. Our cell cycle analysis system, which is also compatible with adherent cells, is fully automated and freely available, providing detailed insights from hundreds of cells under various conditions. This report presents a valuable tool for advancing cancer research and drug development by enabling comprehensive, automated cell cycle analysis in both adherent and non-adherent cells.